BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+16.15%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$11.4B
AUM Growth
+$11.4B
(-5.2%)
Cap. Flow
-$1.07B
Cap. Flow
% of AUM
-9.36%
Top 10 Holdings %
Top 10 Hldgs %
75.13%
Holding
140
New
10
Increased
24
Reduced
17
Closed
12
Top Buys
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$1.18B |
| 2 |
AbbVie
ABBV
|
$966M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$96.5M |
| 4 |
DYAX
DYAX CORPORATION
DYAX
|
$50.5M |
| 5 |
ATYR
aTyr Pharma
ATYR
|
$43.2M |
Top Sells
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
$2.31B |
| 2 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
$1.14B |
| 3 |
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
|
$44.8M |
| 4 |
Vanda Pharmaceuticals
VNDA
|
$17M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$14.4M |
Sector Composition
| 1 | Healthcare | 72.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Madrigal Pharmaceuticals
MDGL
$9.7B
| – | – |
-489,053
| Closed | -$949K |
|
127
Lipocine
LPCN
$15.7M
| – | – |
-489,175
| Closed | -$3.38M |
|